Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, made an important announcement today that the first patient has been admitted in the Phase 2a clinical study. This study will be pivotal iin evaluating AV-001 in hospitalized patients experiencing severe symptoms COVID-19 disease.
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.